Daratumumab in newly diagnosed MM - incorporating lessons learnt from CASSIOPEIA, MAIA and beyond

Nat Rev Clin Oncol. 2022 Jan;19(1):3-4. doi: 10.1038/s41571-021-00581-2.
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Humans
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / mortality
  • Progression-Free Survival

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • daratumumab